ClinicalTrials.gg
RecruitingNCT07677215Updated Nov 5, 2026

ACB and iPACK Blocks With Intravenous Dexamethasone and Perineural Dexmedetomidine in Total Knee Arthroplasty

An interventional study of Ropivacaine 0.2% Injectable Solution and Dexamethasone in Knee Osteoarthritis, sponsored by Poznan University of Medical Sciences. Recruiting at 2 sites in Poland. Open to participants aged 60 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Poznan University of Medical Sciences · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 5, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
60 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing dexamethasone in Osteoarthritis, Knee — 2 open to participants now, 2 under way, none of them phase 3. Dexamethasone · Osteoarthritis, Knee.

Planned enrollment
3rd of 12
120 · median 90
Started
2026
with 1 other
No phase
2 of 12
1 open now
Registered
12th of 12
by date
Lead sponsor
5 of 12
Poznan University of Medical Sciences

Among the 12 studies testing dexamethasone in Osteoarthritis, Knee, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is one of 2 with no phase, and was the 12th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

2 of the 12 studies testing dexamethasone in Osteoarthritis, Knee are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 60 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing dexamethasone in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

This prospective randomized controlled trial aims to compare the analgesic efficacy and safety of three adjuvant strategies for ultrasound-guided Adductor Canal Block (ACB) and iPACK block in patients undergoing elective total knee arthroplasty under spinal anesthesia. All participants will receive standardized spinal anesthesia with 0.5% ropivacaine combined with ACB and iPACK blocks using 0.2% ropivacaine. Patients will be randomized into one of three groups: standard ACB + iPACK without adjuvants, ACB + iPACK with intravenous dexamethasone 8 mg, or ACB + iPACK with intravenous dexamethasone 8 mg combined with perineural dexmedetomidine added to both regional blocks.

The primary outcome will be total postoperative opioid consumption during the first 48 hours after surgery expressed as intravenous morphine equivalents. Secondary outcomes will include pain intensity at rest and during movement, duration of analgesia, time to first rescue analgesia, quadriceps muscle strength, early mobilization, adverse events, inflammatory markers, and length of hospital stay.

Read the detailed description

Postoperative pain following total knee arthroplasty (TKA) remains a major clinical challenge and may negatively affect early mobilization, rehabilitation, patient satisfaction, and postoperative recovery. Inadequate pain control after TKA is associated with increased opioid consumption and opioid-related adverse events, including nausea, vomiting, sedation, urinary retention, respiratory depression, and postoperative delirium, particularly in elderly patients.

Ultrasound-guided Adductor Canal Block (ACB) combined with iPACK (Infiltration between the Popliteal Artery and Capsule of the Knee) block has become an increasingly popular regional anesthesia strategy for TKA because it may provide effective analgesia while preserving quadriceps muscle strength and facilitating early mobilization. The ACB primarily targets the sensory innervation of the anterior and medial aspects of the knee, whereas the iPACK block supplements analgesia of the posterior knee capsule.

Several adjuvant medications have been investigated to prolong the duration and improve the quality of peripheral nerve blocks. Intravenous dexamethasone is widely used as a perioperative analgesic adjunct and may prolong postoperative analgesia while also reducing postoperative nausea and vomiting. Perineural dexmedetomidine has been shown to prolong sensory blockade, improve analgesia quality, and reduce opioid requirements. However, the optimal combination of systemic and perineural adjuvants for ACB and iPACK blocks in TKA remains unclear.

The aim of this prospective randomized controlled trial is to compare three perioperative analgesic strategies in patients undergoing elective primary unilateral total knee arthroplasty under spinal anesthesia:

Standard ACB + iPACK without adjuvants, ACB + iPACK with intravenous dexamethasone 8 mg, ACB + iPACK with intravenous dexamethasone 8 mg combined with perineural dexmedetomidine.

All participants will receive standardized spinal anesthesia with 0.5% ropivacaine (3-4 mL). Ultrasound-guided ACB and iPACK blocks will be performed using 20 mL of 0.2% ropivacaine for each block. In the dexmedetomidine group, 12.5 µg of dexmedetomidine will be added to each regional block.

The primary endpoint of the study will be total postoperative opioid consumption during the first 48 postoperative hours expressed as intravenous morphine equivalents. Secondary endpoints will include postoperative pain scores at rest and during movement, time to first rescue analgesia, duration of analgesia, quadriceps muscle strength, early mobilization, opioid-related adverse events, dexmedetomidine-related adverse events such as bradycardia and hypotension, inflammatory markers, and length of hospital stay.

The study hypothesis is that intravenous dexamethasone will improve postoperative analgesia compared with standard ACB + iPACK alone, while the addition of low-dose perineural dexmedetomidine will further prolong analgesia duration and reduce opioid consumption without significantly increasing adverse events or impairing postoperative mobilization.

03

Conditions studied

  • Knee Osteoarthritis
04

Who can participate

Ages eligible
60 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 60 and 100 years
  • Scheduled for elective primary unilateral total knee arthroplasty
  • (ASA) physical status I-III
  • Ability to understand study procedures and provide written
  • Eligibility for spinal anesthesia and ultrasound-guided regional anesthesia according to institutional standards

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to ropivacaine, dexamethasone, dexmedetomidine, or any study-related medication
  • to spinal anesthesia or peripheral nerve blocks
  • Coagulation disorders or anticoagulant therapy preventing safe regional anesthesia
  • Infection at the planned puncture site or systemic infection
  • Severe neurological disorders affecting lower limb sensory or motor function
  • Severe hepatic, renal, or uncontrolled cardiovascular disease
  • bradycardia or advanced atrioventricular conduction abnormalities
  • Chronic opioid use for more than 3 months before surgery
  • Uncontrolled diabetes mellitus or contraindications to dexamethasone administration
  • Inability or refusal to provide written
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    ACB + iPACK Without Adjuvants

    Participants will receive standardized spinal anesthesia with 0.5% ropivacaine (3-4 mL) combined with ultrasound-guided Adductor Canal Block (ACB) and iPACK block using 20 mL of 0.2% ropivacaine for each block. No adjuvant medications will be administered. Standardized multimodal postoperative analgesia will be provided according to institutional protocol.

    Drug: Ropivacaine 0.2% Injectable Solution

  • Experimental
    ACB + iPACK With Intravenous Dexamethasone

    Participants will receive standardized spinal anesthesia with 0.5% ropivacaine (3-4 mL) combined with ultrasound-guided Adductor Canal Block (ACB) and iPACK block using 20 mL of 0.2% ropivacaine for each block. Intravenous dexamethasone 8 mg will be administered perioperatively. Standardized multimodal postoperative analgesia will be provided according to institutional protocol.

    Drug: Dexamethasone

  • Experimental
    ACB + iPACK With Intravenous Dexamethasone and Perineural Dexmedetomidine

    Participants will receive standardized spinal anesthesia with 0.5% ropivacaine (3-4 mL) combined with ultrasound-guided Adductor Canal Block (ACB) and iPACK block using 20 mL of 0.2% ropivacaine for each block. Perineural dexmedetomidine 12.5 µg will be added to each regional block. Intravenous dexamethasone 8 mg will be administered perioperatively. Standardized multimodal postoperative analgesia will be provided according to institutional protocol.

    Drug: Dexmedetomidine

Interventions

  • DrugRopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ropivacaine 0.2% used for ultrasound-guided ACB and iPACK blocks (20 mL per block).

    Also known as: Ropimol

  • Intravenous dexamethasone 8 mg administered perioperatively.

    Also known as: Dexaven

  • Perineural dexmedetomidine 12.5 μg added to each regional block (ACB and iPACK).

    Also known as: Dexdor

06

What researchers measure

Primary outcomes

  1. Total postoperative opioid consumption during the first 48 hours after surgery

    Total postoperative opioid consumption will be recorded during the first 48 hours after total knee arthroplasty and converted to intravenous morphine milligram equivalents.

    Time frame: 48 hours after surgery

Secondary outcomes

  1. Pain intensity at rest

    Pain intensity at rest will be assessed using the Numeric Rating Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain.

    Time frame: 6 hours after surgery

  2. Pain intensity at rest

    Pain intensity at rest will be assessed using the Numeric Rating Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain.

    Time frame: 12 hours after surgery

  3. Pain intensity at rest

    Pain intensity at rest will be assessed using the Numeric Rating Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain.

    Time frame: 24 hours after surgery

  4. Pain intensity at rest

    Pain intensity at rest will be assessed using the Numeric Rating Scale, where 0 indicates no pain and 10 indicates the worst imaginable pain.

    Time frame: 48 hours after surgery

  5. Pain intensity during movement assessed using the Numeric Rating Scale

    Pain intensity during movement will be assessed using the Numeric Rating Scale during active or passive knee movement, where 0 indicates no pain and 10 indicates the worst imaginable pain.

    Time frame: 6 hours postoperatively

  6. Pain intensity during movement assessed using the Numeric Rating Scale

    Pain intensity during movement will be assessed using the Numeric Rating Scale during active or passive knee movement, where 0 indicates no pain and 10 indicates the worst imaginable pain.

    Time frame: 12 hours postoperatively

  7. Pain intensity during movement assessed using the Numeric Rating Scale

    Pain intensity during movement will be assessed using the Numeric Rating Scale during active or passive knee movement, where 0 indicates no pain and 10 indicates the worst imaginable pain.

    Time frame: 24 hours postoperatively

  8. Pain intensity during movement assessed using the Numeric Rating Scale

    Pain intensity during movement will be assessed using the Numeric Rating Scale during active or passive knee movement, where 0 indicates no pain and 10 indicates the worst imaginable pain.

    Time frame: 48 hours postoperatively

  9. Time to first rescue analgesia

    Time from the end of surgery to the first request for or administration of rescue analgesic medication.

    Time frame: 48 hours after surgery

  10. Quadriceps muscle strength of the operated limb

    Quadriceps muscle strength of the operated limb will be assessed using a standardized motor strength scale.

    Time frame: 6 hours postoperatively

  11. Quadriceps muscle strength of the operated limb

    Quadriceps muscle strength of the operated limb will be assessed using a standardized motor strength scale.

    Time frame: 12 hours postoperatively

  12. Quadriceps muscle strength of the operated limb

    Quadriceps muscle strength of the operated limb will be assessed using a standardized motor strength scale.

    Time frame: 24 hours postoperatively

  13. Quadriceps muscle strength of the operated limb

    Quadriceps muscle strength of the operated limb will be assessed using a standardized motor strength scale.

    Time frame: 48 hours postoperatively

  14. Time to first postoperative mobilization

    Time from the end of surgery to the first successful mobilization with assistance, according to the institutional rehabilitation protocol.

    Time frame: 48 hours postoperatively

  15. Length of hospital stay

    Length of hospital stay will be defined as the number of days from surgery to hospital discharge.

    Time frame: up to 7 days

07

Study locations

2 of 2 sites recruiting
  • The John Paul II Catholic University of Lublin
    Lublin, Poland
    Recruiting
    • Michał Borys, MD PhD · Contact
  • Poznan University of Medical Sciences
    Poznan, 62-701, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the reported results will be made available to qualified researchers upon reasonable request after publication of the primary study results. Shared data may include demographic data, perioperative variables, postoperative pain scores, opioid consumption, adverse events, and other study-related outcomes. Data will be provided after removal of all direct identifiers in accordance with applicable data protection regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: Data will become available beginning 6 months after publication of the primary study results and will remain available for 5 years.

Access criteria: Access to de-identified participant data will be provided to researchers whose proposed use of the data has been approved by the principal investigators. Requests should include a methodologically sound research proposal. Data sharing agreements may be required before data release.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Sep 2027, 15 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 15 months is below that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → May 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 30, 2026
StartActual
May 20, 2026was Jul 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • The John Paul II Catholic University of Lublin · Lublin, Polandno status→Recruiting
  • Poznan University of Medical Sciences · Poznan, Polandno status→Recruiting
Nov 5, 2026
Start date
Jul 1, 2026→May 20, 2026 (actual)
Nov 5, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Poznan University of Medical Sciences · Poznan, PolandContact added m•••@ump.edu.pl · •••8303
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • The John Paul II Catholic University of Lublin · Lublin, Polandno status→Recruiting
    • Poznan University of Medical Sciences · Poznan, Polandno status→Recruiting
    Start date Jul 1, 2026→May 20, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Poznan University of Medical Sciences · Poznan, PolandContact added m•••@ump.edu.pl · •••8303
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07677215
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
May 20, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Malgorzata Reysner, MD PhD
Contact
mreysner@ump.edu.pl
+48 61 8310122
Tomasz Reysner, MD PhD
Contact
treysner@ump.edu.pl
+48 61 8310122
Malgorzata Reysner, MD PhD
study chair · Poznan University of Medical Sciences
Michał Borys, MD PhD
study director · The John Paul II Catholic University of Lublin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone · Dexmedetomidine

Start the discussion